Psychedelic Business News Spotlight: March 19, 2021
This week in psychedelic business news, quick dissolve LSD, novel psychedelic molecules move into investigational studies, and more.
Author: Jennifer Walker-Journey
These 24 Psychedelic Patents Are Paving the Way for Medicine 2.0
Patents of psychedelic substances are paving the way for new research and treatment options for a variety of diseases.
Researchers to Hone In On Most Therapeutic Doses of LSD
New research is looking into the optimal dose of LSD to further enhance the therapeutic benefits of the psychedelic.
Oregon Announces Creation of the Psilocybin Advisory Board
The first state to legalize therapeutic use of psilocybin, Oregon now has an advisory board to help build its regulations.
Psychotherapist Kelli Foulkrod Takes a Holistic Approach to Trauma Treatment With Psychedelics
Psychotherapist Kelli Foulkrod uses psychedelics with her patients as part of her holistic treatment to mental health issues.
New York Bill Would Decriminalize Psilocybin
Proposed legislation in the state of New York would decriminalize psilocybin, the psychedelic compound in some types of mushrooms.
Psychedelics Officially Decriminalized In Washington D.C.
After voters approved a measure that decriminalized psychedelics in Washington D.C. last November, the measure is now in effect.
Silo Wellness Ketamine Retreats to Focus on Healing Power of Nature
Silo Wellness Inc., a wellness company in the psychedelics and functional mushroom space, is offering ketamine-assisted psychedelics wellness retreats
U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for Addiction
Awakn Life Sciences is looking at psychedelics for addiction, namely MDMA and ketamine for alcohol use disorder.
Small Pharma Clinical Trials to Study DMT for Treatment-Resistant Depression
Small Pharma is going into clinical trials to look at DMT for depression relief. The UK company says it believes benefits will be immediate.
End of content
End of content